The deal to merge into Recursion caps off a tumultuous year for Exscientia, which uses AI to aid drug discovery. (asbe/iStock/Getty Images Plus) After a year defined by pipeline cuts, the departure of ...
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
"For 2026, we are maintaining our cash operating expense guidance of less than $390 million." (CFO & President of Recursion UK Taylor). "We expect multiple clinical readouts over the next 12 to 18 ...
Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...
SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results